AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer

NCT00427973 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

17

Enrollment

NIH

Sponsor class

Stopped The study was stopped prior to 2nd stage.

Conditions

Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions

DRUG: cediranib maleate
OTHER: laboratory biomarker analysis
PROCEDURE: computed tomography
PROCEDURE: dynamic contrast-enhanced magnetic resonance imaging
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)